Rheumatoid Arthritis
Conditions
Keywords
patient-reported outcomes, rheumatoid arthritis, real world evidence, wearable digital technology, real world data, rheumatology, patients, patient-generated health data, mobile technology
Brief summary
Rheumatoid arthritis patients being seen at one of the participating clinical sites in a U.S. network of community rheumatology practices who are starting treatment on adalimumab or upadacitinib will be enrolled into a 24-week study combining clinical data from physicians, self-reported patient outcomes from the ArthritisPower registry app, and activity and sleep data from a Fitbit wearable device. The primary objective of this study is: • Evaluate longitudinal associations between biometric sensor data (activity and sleep measures), physician-derived data (including clinical disease activity index (CDAI), Rheumatoid Factor (RF) lab results and other relevant biomarkers, current medications and disease duration), and patient-reported outcomes (PROs) (including PROMIS pain interference, physical function, fatigue, sleep disturbance, satisfaction with participation in discretionary social activities, and anxiety). The secondary objectives of this study are as follows: * Explore the reliability and predictive validity of biometric sensor data to classify changes in RA disease activity and associated symptoms, including PROs. * To assess adherence and predictors of adherence with use of biometric sensor * Assess/track changes in upadacitinib and adalimumab patients using combined physician, PRO and biosensor data.
Interventions
None listed
Sponsors
University of Alabama at Birmingham
Illumination Health
Global Healthy Living Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 19 and above who are adults (i.e., the age of majority where they reside) * Diagnosis of RA by a physician (as indicated by survey screening questions) * Currently being seen by a U.S. rheumatologist * Starting on the day of enrollment (with no prior use ever) or soon-to-initiate (i.e. in the next 28 days) upadacitinib or adalimumab for RA * Ability to walk without the use of assistive devices; * Have access to a computer or smartphone to take health assessments and a survey; * Already own a smartphone (iPhone or Android); iPhone 4S and later or Android 4.3 and later * Are willing to join the ArthritisPower patient registry; * Are willing to download the ArthritisPower app; * Are willing to contribute daily and weekly ePROs for at least at 89 days, and health activity tracker data for at least 84 days (lead-in period minimum of 5 days plus main study period 84 days). Some participants may contribute data more than 89 days if there was a lag in receiving their medication and hence later medication start date; * Are willing to wear the smartwatch while sleeping; * Are willing to complete the 7-day run-in requirements (i.e. completing daily PRO assessments for at least 5 of 7 days); * Have started their medication within 30 days of enrolling in the study (i.e. enrolling in ArthritisPower) * Will not be out of internet access (wifi and/or mobile data) for 4 or more consecutive days during the study; and * Willing to be contacted by e-mail/text message and/or phone by the study coordinator if participants fail to adhere to the study Protocol or for any study related assistance as required. * Clinician must collect a CDAI (including the raw scores for the four components - patient global, physician global and tender and swollen joint count) on day of enrollment. * CDAI must be \>10 * Must have rheumatoid and CCP antibody lab results available, or collect those labs (as part of standard of care during the enrollment visit) if not available
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlations between patient reported outcomes (PROs), wearable data, and physician derived data | PROs and Wearable Data is collected daily. Physician Derived outcomes are collected at baseline and at follow up appointment at 2-6 months post baseline. | Pearson correlation coefficient between patient reported outcomes, wearable data, and physician derived data PROs include:Daily- Pain NRS 0-10; Fatigue NRS 0-10; Duration of Morning Joint Stiffness Weekly- Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5); Patient Global Assessment; PROMIS Pain Interference CAT; PROMIS Physical Function CAT; PROMIS Fatigue CAT; PROMIS Sleep Disturbance CAT Monthly- PROMIS Satisfaction with Participation in Discretionary Social Activities; PROMIS Anxiety Wearable Data include:Activity- steps, distance, energy expenditure, metabolic equivalents, time walking per day, time in activity intensity per day, active time, aerobic time Heart rate-beats per minute, time in heart rate zones; Sleep-time asleep/restless/awake, and derived variables. Physician derived outcomes include:Clinical Disease Activity Index (CDAI); RA Clinical Labs (Rheumatoid Factor lab results); Current prescription medications for RA; Years since RA diagnosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in RA disease activity and associated symptoms | CDAI is collected at baseline and then again at a follow up appointment from 2-6 months after baseline. | Changes in RA will be measured using change in Clinical Disease Activity Index (CDAI) between baseline and follow up visits |
| Adherence to PRO measures | PROs Data is collected daily for up to 6 months | Adherence\*: percent of days completing ePROs |
| Adherence to wearing Fitbit | Wearable Data is collected daily for up to 6 months | Adherence\*: percent of days wearing Fitbit |
| Predictors of adherence | PROs and Wearable Data is collected daily for up to 6 months | Using Patient Reported Outcomes and wearable data to predict who is adherent to study protocol PROs include:Daily- Pain NRS 0-10; Fatigue NRS 0-10; Duration of Morning Joint Stiffness Weekly- Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5); Patient Global Assessment; PROMIS Pain Interference CAT; PROMIS Physical Function CAT; PROMIS Fatigue CAT; PROMIS Sleep Disturbance CAT Monthly- PROMIS Satisfaction with Participation in Discretionary Social Activities; PROMIS Anxiety Wearable Data include:Activity- steps, distance, energy expenditure, metabolic equivalents, time walking per day, time in activity intensity per day, active time, aerobic time Heart rate-beats per minute, time in heart rate zones; Sleep-time asleep/restless/awake, and derived variables. |
| Changes in upadacitinib and adalimumab patients using combined physician, PRO and biosensor data. | PROs Data is collected daily from baseline physician appointment until follow up appointment. Physician derived outcomes are collected at baseline and then again at a follow up appointment from 2-6 months after baseline. | Changes will be measured using numerical scales for PROs. PROs include:Daily- Pain NRS 0-10; Fatigue NRS 0-10; Duration of Morning Joint Stiffness Weekly- Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5); Patient Global Assessment; PROMIS Pain Interference CAT; PROMIS Physical Function CAT; PROMIS Fatigue CAT; PROMIS Sleep Disturbance CAT Monthly- PROMIS Satisfaction with Participation in Discretionary Social Activities; PROMIS Anxiety Wearable Data include:Activity- steps, distance, energy expenditure, metabolic equivalents, time walking per day, time in activity intensity per day, active time, aerobic time Heart rate-beats per minute, time in heart rate zones; Sleep-time asleep/restless/awake, and derived variables. Physician derived outcomes include:Clinical Disease Activity Index (CDAI); RA Clinical Labs (Rheumatoid Factor lab results); Current prescription medications for RA; Years since RA diagnosis |
Countries
United States
Outcome results
None listed